Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    Biopharma firm UCB brings new arthritis therapy to China

    By Zhou Wenting in Shanghai | chinadaily.com.cn | Updated: 2019-12-16 16:59
    Share
    Share - WeChat

    Belgium-based global biopharmaceutical company UCB announced the commercial launch of an innovative biological therapy to treat moderate-to-severe active rheumatoid arthritis (RA) for adult patients in China, marking the expansion of company's business footprint to immune system diseases in the country.

    The injection that patients are suggested to take every two weeks is the first biological agent approved in China to be used for female RA patients both during pregnancy and lactation if clinically needed.

    Doctors said RA is an autoimmune disease that causes chronic joint inflammation and affects 5 million people in China. The number of women patients suffering from the disease is three times that of the opposite gender, and women at childbearing age usually have to face the dilemma between postponing starting a family and suspending disease treatment with traditional therapies.

    Tian Xinping, chief physician of the department of rheumatology and immunology of the Peking Union Medical College Hospital, said if the disease is not well controlled for women before and during pregnancy, it may increase the risk of adverse pregnancy outcomes, such as preterm birth, low birth weight and preeclampsia. RA also comes with high disease relapse rate after giving birth, she said.

    Taco van Tiel, vice-president and head of international markets of UCB, said the product with novel molecular structure made world debut in Switzerland 12 years ago and so far has been available in 56 countries and benefiting over 380,000 patients.

    "We're delighted to bring this novel medicine to Chinese patients living with challenging chronic inflammatory conditions. UCB has a long heritage in immunology and now China has built an active pipeline of innovative portfolios reflecting UCB's global strengths," he said.

    Wu Xin, managing director of UCB China, said about five innovative molecules, including those treating autoimmune disease and osteoporosis, are scheduled by the company to be launched in the China market over the next five years.

    "For two drugs, China is part of the global Phase III clinical trial simultaneously," he said.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    久久久无码精品亚洲日韩京东传媒| 无码人妻精品一区二区三区99不卡 | 国产成人无码免费看片软件| 人妻AV中出无码内射| 国色天香中文字幕在线视频| 人妻少妇乱子伦无码视频专区 | 中文字幕日韩理论在线| 亚洲精品无码久久久| 久久国产精品无码一区二区三区| 人妻系列AV无码专区| 日本中文字幕免费高清视频| 无码人妻精品一区二区蜜桃AV| 无码无套少妇毛多18PXXXX| 无码人妻丰满熟妇啪啪网站| 日本一区二区三区精品中文字幕| 中文字幕精品无码一区二区 | 日韩人妻无码精品久久免费一| 最近最新中文字幕视频| 久久精品中文字幕第23页| 色欲狠狠躁天天躁无码中文字幕| 免费 无码 国产在线观看观| 久久ZYZ资源站无码中文动漫| 无码精品第一页| 久久精品无码一区二区三区免费| 免费无码中文字幕A级毛片| 一二三四在线播放免费观看中文版视频| 97精品人妻系列无码人妻| 日韩精品无码视频一区二区蜜桃| 免费在线中文日本| 欧美日韩中文在线视免费观看| 亚洲中文字幕无码爆乳av中文| 国产精品一级毛片无码视频| 国产精品免费无遮挡无码永久视频| 无码日韩人妻精品久久蜜桃| 无码专区AAAAAA免费视频| 亚洲爆乳精品无码一区二区三区 | 婷婷四虎东京热无码群交双飞视频| 最近免费中文字幕大全免费 | 亚洲av午夜国产精品无码中文字| 日本精品久久久中文字幕| 国产精品亚洲w码日韩中文|